GIOTRIF® :
The 1^st choice in 1^st-line

Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1^st-line EGFR M+ NSCLC^1-4*

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC

Document ID: PC-MY-102569

25/07/2022

Author: Boehringer Ingelheim

123,000
Views

100k 340